ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 137 filers reported holding ENANTA PHARMACEUTICALS INC in Q4 2015. The put-call ratio across all filers is 8.04 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $196,235 | -42.4% | 17,568 | +10.3% | 0.00% | – |
| Q2 2023 | $340,881 | -45.9% | 15,929 | +2.2% | 0.00% | -100.0% |
| Q1 2023 | $630,298 | -13.1% | 15,586 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $725,061 | -10.3% | 15,586 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $808,446 | +9.4% | 15,586 | -0.3% | 0.00% | -50.0% |
| Q2 2022 | $739,000 | -33.6% | 15,637 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $1,113,000 | -1.4% | 15,637 | +3.6% | 0.00% | 0.0% |
| Q4 2021 | $1,129,000 | +55.9% | 15,099 | +18.6% | 0.00% | +100.0% |
| Q3 2021 | $724,000 | +30.7% | 12,733 | +1.1% | 0.00% | 0.0% |
| Q2 2021 | $554,000 | -15.3% | 12,595 | -5.0% | 0.00% | 0.0% |
| Q1 2021 | $654,000 | +20.4% | 13,251 | +2.6% | 0.00% | 0.0% |
| Q4 2020 | $543,000 | +5.4% | 12,909 | +14.7% | 0.00% | 0.0% |
| Q3 2020 | $515,000 | -9.6% | 11,250 | -0.8% | 0.00% | 0.0% |
| Q2 2020 | $570,000 | -16.9% | 11,343 | -14.9% | 0.00% | -50.0% |
| Q1 2020 | $686,000 | -14.4% | 13,330 | +2.8% | 0.00% | 0.0% |
| Q4 2019 | $801,000 | +13.8% | 12,968 | +10.6% | 0.00% | 0.0% |
| Q3 2019 | $704,000 | -29.0% | 11,720 | -0.3% | 0.00% | 0.0% |
| Q2 2019 | $992,000 | -11.8% | 11,760 | -0.2% | 0.00% | -33.3% |
| Q1 2019 | $1,125,000 | +31.6% | 11,780 | -2.4% | 0.00% | +50.0% |
| Q4 2018 | $855,000 | +10.2% | 12,075 | +32.9% | 0.00% | 0.0% |
| Q3 2018 | $776,000 | +0.5% | 9,086 | +36.5% | 0.00% | 0.0% |
| Q2 2018 | $772,000 | +34.0% | 6,657 | -6.5% | 0.00% | +100.0% |
| Q1 2018 | $576,000 | +29.7% | 7,119 | -5.8% | 0.00% | 0.0% |
| Q4 2017 | $444,000 | +13.6% | 7,558 | -9.5% | 0.00% | 0.0% |
| Q3 2017 | $391,000 | +30.3% | 8,350 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $300,000 | +32.2% | 8,350 | +13.3% | 0.00% | 0.0% |
| Q1 2017 | $227,000 | -72.4% | 7,373 | -70.0% | 0.00% | -50.0% |
| Q4 2016 | $823,000 | -29.7% | 24,576 | -44.1% | 0.00% | 0.0% |
| Q3 2016 | $1,170,000 | +73.8% | 43,962 | +44.1% | 0.00% | 0.0% |
| Q2 2016 | $673,000 | -24.9% | 30,511 | 0.0% | 0.00% | 0.0% |
| Q1 2016 | $896,000 | -24.6% | 30,511 | -15.2% | 0.00% | -33.3% |
| Q4 2015 | $1,188,000 | -92.4% | 35,991 | -91.7% | 0.00% | -92.3% |
| Q3 2015 | $15,714,000 | -6.1% | 434,802 | +16.9% | 0.04% | +2.6% |
| Q2 2015 | $16,735,000 | +6121.2% | 371,998 | +6932.1% | 0.04% | +3700.0% |
| Q4 2014 | $269,000 | +28.7% | 5,290 | 0.0% | 0.00% | – |
| Q3 2014 | $209,000 | -8.3% | 5,290 | 0.0% | 0.00% | -100.0% |
| Q2 2014 | $228,000 | – | 5,290 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 1,055,719 | $35,367,000 | 12.68% |
| GREAT POINT PARTNERS LLC | 828,253 | $27,746,000 | 5.70% |
| McClain Value Management LLC | 116,153 | $3,891,000 | 4.80% |
| Stonepine Capital Management, LLC | 231,913 | $7,769,000 | 4.63% |
| ARMISTICE CAPITAL, LLC | 228,000 | $7,638,000 | 1.81% |
| Opaleye Management Inc. | 90,000 | $3,015,000 | 1.78% |
| Matarin Capital Management, LLC | 257,268 | $8,618,478,000 | 0.97% |
| HAYS ADVISORY LLC | 116,939 | $3,917,000 | 0.87% |
| Granahan Investment Management | 496,025 | $16,617,000 | 0.57% |
| AlphaMark Advisors, LLC | 33,000 | $1,106,000 | 0.57% |